WuXi Biologics (2269.HK) stock price, revenue, and financials

WuXi Biologics market cap is $511.5 b, and annual revenue was ¥5.61 b in FY 2020

$511.5 B

2269.HK Mkt cap, 21-Sept-2021

¥5.6 B

WuXi Biologics Revenue FY, 2020
WuXi Biologics Revenue growth (FY, 2019 - FY, 2020), %41%
WuXi Biologics Gross profit (FY, 2020)2.5 B
WuXi Biologics Gross profit margin (FY, 2020), %45.1%
WuXi Biologics Net income (FY, 2020)1.7 B
WuXi Biologics Cash, 31-Dec-20207.1 B
WuXi Biologics EV507.8 B
Get notified regarding key financial metrics and revenue changes at WuXi BiologicsLearn more
Banner background

WuXi Biologics Revenue

WuXi Biologics revenue was ¥5.61 b in FY, 2020 which is a 40.9% year over year increase from the previous period.

Embed Graph

WuXi Biologics Revenue Breakdown

Embed Graph

WuXi Biologics revenue breakdown by geographic segment: 43.9% from PRC, 44.2% from North America, 8.0% from Europe and 4.0% from Other

WuXi Biologics Income Statement

Annual

CNYFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.6b2.5b4.0b5.6b

Revenue growth, %

57%57%41%

Cost of goods sold

958.3m1.5b2.3b3.1b

Gross profit

660.6m1.0b1.7b2.5b

Gross profit Margin, %

41%40%42%45%

Sales and marketing expense

27.6m42.4m77.1m94.4m

R&D expense

74.5m169.3m259.7m303.7m

General and administrative expense

134.0m227.7m367.3m511.4m

Operating expense total

252.3m439.4m704.0m909.6m

Interest expense

35.7m19.6m42.7m

Pre tax profit

303.7m737.7m1.1b2.0b

Income tax expense

51.1m107.3m116.3m273.1m

Net Income

252.6m630.5m1.0b1.7b

EPS

0.20.50.80.4

Half Year

CNYH1, 2018H1, 2019H1, 2020

Revenue

1.1b1.6b1.9b

Cost of goods sold

639.7m936.1m1.2b

Gross profit

414.7m671.0m787.3m

Gross profit Margin, %

39%42%40%

Sales and marketing expense

19.9m26.3m48.5m

R&D expense

56.2m109.1m124.4m

General and administrative expense

87.1m149.7m203.4m

Operating expense total

163.2m285.2m376.3m

Interest expense

4.6m22.4m

Pre tax profit

285.1m512.0m705.1m

Income tax expense

35.5m62.6m(25.6m)

Net Income

249.6m449.5m730.7m

EPS

0.20.30.5

WuXi Biologics Balance Sheet

Annual

CNYFY, 2017FY, 2018FY, 2019FY, 2020

Cash

503.9m4.1b6.2b7.1b

Accounts Receivable

314.3m762.9m1.3b2.3b

Prepaid Expenses

927.0k3.2m4.1m6.6m

Inventories

135.5m227.2m399.4m1.1b

Current Assets

3.0b5.7b9.7b14.2b

PP&E

1.8b2.9b6.3b12.0b

Goodwill

185.4m185.4m

Total Assets

4.8b9.4b17.6b29.0b

Accounts Payable

137.3m221.0m185.8m646.0m

Short-term debt

532.6m827.8m

Current Liabilities

798.1m1.3b2.9b4.5b

Long-term debt

1.7b2.5b

Non-Current Liabilities

26.5m80.2m1.8b3.6b

Total Debt

2.2b3.3b

Total Liabilities

824.6m1.4b4.7b8.1b

Common Stock

192.0k202.0k214.0k225.0k

Additional Paid-in Capital

3.4b6.7b10.3b

Retained Earnings

394.2m962.2m1.9b

Total Equity

4.0b8.0b12.9b20.9b

Debt to Equity Ratio

0.2 x0.2 x

Debt to Assets Ratio

0.1 x0.1 x

Financial Leverage

1.2 x1.2 x1.4 x1.4 x

Half Year

CNYH1, 2018H1, 2019H1, 2020

Cash

4.4b2.9b3.7b

Accounts Receivable

576.7m872.0m1.7b

Prepaid Expenses

8.2m7.2m7.1m

Inventories

243.3m318.9m611.8m

Current Assets

5.8b5.0b9.4b

PP&E

2.2b3.6b9.1b

Goodwill

185.4m

Total Assets

8.6b10.2b20.7b

Accounts Payable

142.2m250.7m355.4m

Short-term debt

31.5m827.9m

Current Liabilities

990.2m1.3b3.2b

Long-term debt

216.6m2.9b

Non-Current Liabilities

69.0m319.1m3.8b

Total Debt

248.1m3.7b

Total Liabilities

1.1b1.7b6.9b

Common Stock

201.0k204.0k216.0k

Additional Paid-in Capital

6.6b6.7b10.3b

Retained Earnings

636.2m1.4b2.6b

Total Equity

7.5b8.5b13.8b

Debt to Equity Ratio

0 x0.3 x

Debt to Assets Ratio

0 x0.2 x

Financial Leverage

1.1 x1.2 x1.5 x

WuXi Biologics Cash Flow

Annual

CNYFY, 2017FY, 2018FY, 2019

Depreciation and Amortization

122.7m145.9m224.4m

Accounts Receivable

(203.1m)(452.5m)(643.9m)

Inventories

(138.9m)(95.7m)(94.0m)

Accounts Payable

203.9m183.5m579.6m

Cash From Operating Activities

360.3m761.6m1.2b

Purchases of PP&E

(670.6m)(1.3b)(3.2b)

Cash From Investing Activities

(2.2b)(416.1m)(4.5b)

Long-term Borrowings

(1.2b)(162.2m)

Cash From Financing Activities

2.2b3.2b5.4b

Net Change in Cash

334.8m3.6b2.1b

Interest Paid

36.3m49.8m

Income Taxes Paid

43.3m52.1m78.0m

Half Year

CNYH1, 2018H1, 2019H1, 2020

Cash From Operating Activities

122.2m221.9m430.6m

Purchases of PP&E

(525.0m)(753.7m)(2.9b)

Cash From Investing Activities

533.6m(1.4b)(4.0b)

Long-term Borrowings

(8.9m)(165.2m)

Cash From Financing Activities

3.2b4.1m1.0b

Net Change in Cash

3.9b(1.2b)(2.5b)

Interest Paid

5.7m35.7m

WuXi Biologics Ratios

CNYFY, 2017

Revenue/Employee

636.6k

Financial Leverage

1.2 x

WuXi Biologics Operating Metrics

WuXi Biologics's Backlog was reported to be $11.3b in FY, 2020.
FY, 2017H1, 2018FY, 2018H1, 2019FY, 2019H1, 2020Oct, 2020FY, 2020

Pre-clinical Projects

909897106121141161169

Backlog

$1.48 b$1.78 b$3.6 b$5.1 b$10.3 b$11.32 b

Backlog (Upcoming Potential Milestone Fees)

$1 b$1.25 b$2.01 b$3.42 b$3.93 b$4.7 b

Commercial Manufacturing Projects

11111112

Early-phase Projects

627894102112125127135

Integrated Projects

161187205224250286312334

Late-phase Projects

810131516192328

New Projects

575972

Phase I Projects

6875859393103

Phase II Projects

262727323432

Service Backlog

$476 m$534 m$1.63 b$1.69 b$6.3 b$6.63 b

WuXi Biologics Human Capital

WuXi Biologics's employees are reported to be approximately 55% female and 45% male.
FY, 2019FY, 2018FY, 2017
Female54.8%54.8%54.5%
Male45.2%45.2%45.5%

WuXi Biologics Employee Rating

3.525 votes
Culture & Values
3.2
Work/Life Balance
2.6
Senior Management
3.3
Salary & Benefits
3.2
Career Opportunities
4.5
Source